Controversial report spells doom for EU pharmaceutical parallel trade industry
This article was originally published in RAJ Devices
Executive Summary
Should the recommendations of an unashamedly one-sided, recently-released report be taken up by the European Commission’s Directorate General for Enterprise and Industry (DG Enterprise), the pharmaceutical parallel trade industry could cease to exist. The report, published by the consultancy group Europe Economics in May 2008, but only made public by DG Enterprise this month, has resolutely backed calls for a ban on repackaging and relabelling.